LAUSR

Abstract Thymulin is a peptide hormone which is mainly produced by thymic epithelial cells and it has immune‐modulatory and anti‐inflammatory effects. In this study, we investigated the effects of different doses and various timings of thymulin intraperitoneal administration on spinal microglial activity and intracellular pathways in an inflammatory rat model of Complete Freund's adjuvant (CFA). Thymulin treatment was implemented following CFA‐induced inflammation for 21 days. After conducting behavioral tests (edema and hyperalgesia), the cellular and molecular aspects were examined to detect the thymulin effect on inflammatory factors and microglial activity. We demonstrated that thymulin treatment notably reduced thermal hyperalgesia and paw edema induced by CFA. Furthermore, molecular investigations showed that thymulin reduced CFA‐induced activation of microglia cells, phosphorylation of p38 MAPK and the production of spinal pro‐inflammatory cytokines (TNF‐&agr;, IL‐6) during the study. Our results suggest that thymulin treatment attenuates CFA‐induced inflammation. This effect may be mediated by inhibition of spinal microglia and production of central inflammatory mediators which seems to be associated with the ability of thymulin to reduce p38 MAPK phosphorylation. These data provide evidence of the anti‐hyperalgesic effect of thymulin on inflammatory pain and characterize some of the underlying spinal mechanisms. HighlightsThymulin long‐term treatment is effective in neuro‐inflammation reduction by inhibiting spinal microglia activation and its signaling pathways.Thymulin reduces peripheral inflammation that occurs at the site of CFA injection (edema and hyperalgesia).Thymulin inhibits activation of microglia, reduces production of TNF‐alpha, and inhibits p38 MAPK phosphorylation at lumbar spinal cord level.